Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Treasury Shares (2016 - 2025)

Cytokinetics (CYTK) has disclosed Treasury Shares for 14 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Treasury Shares changed N/A to $2.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.6 million, a N/A change, with the full-year FY2025 number at $2.6 million, changed N/A from a year prior.
  • Treasury Shares was $2.6 million for Q4 2025 at Cytokinetics, up from $1.4 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $2.6 million in Q4 2025 to a low of $1.2 million in Q4 2022.
  • A 4-year average of $1.6 million and a median of $1.4 million in 2021 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: rose 26.7% in 2021, then decreased 14.18% in 2022.
  • Cytokinetics' Treasury Shares stood at $1.4 million in 2021, then fell by 14.18% to $1.2 million in 2022, then rose by 13.21% to $1.4 million in 2023, then soared by 87.27% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Treasury Shares are $2.6 million (Q4 2025), $1.4 million (Q4 2023), and $1.2 million (Q4 2022).